CN114569590B - Medical application of sodium new houttuyfonate - Google Patents
Medical application of sodium new houttuyfonate Download PDFInfo
- Publication number
- CN114569590B CN114569590B CN202210384916.6A CN202210384916A CN114569590B CN 114569590 B CN114569590 B CN 114569590B CN 202210384916 A CN202210384916 A CN 202210384916A CN 114569590 B CN114569590 B CN 114569590B
- Authority
- CN
- China
- Prior art keywords
- sodium
- new houttuyfonate
- colon cancer
- snh
- sodium new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZNDCJNWMQMVSQG-UHFFFAOYSA-N 3-(2-morpholin-4-ylethylamino)propanenitrile Chemical compound N#CCCNCCN1CCOCC1 ZNDCJNWMQMVSQG-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 241000605986 Fusobacterium nucleatum Species 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 206010009944 Colon cancer Diseases 0.000 description 30
- 208000029742 colonic neoplasm Diseases 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 238000011580 nude mouse model Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoyl acetaldehyde Chemical compound CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OTIFKYZNUYSJOU-UHFFFAOYSA-N 1-hydroxy-3-oxododecane-1-sulfonic acid Chemical compound CCCCCCCCCC(=O)CC(O)S(O)(=O)=O OTIFKYZNUYSJOU-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000004020 Brain Abscess Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000000691 Houttuynia cordata Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 241000758742 Saururaceae Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- -1 dodecanoyl aldehyde Chemical class 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- QJQRNDGUWQVAEV-AAFSJPGBSA-M sodium bisulfite adduct Chemical compound [Na+].[O-]S(=O)(=O)C([C@H]1N(C(C2=C3)=O)C=C(C1)/C=C/C(=O)N(C)C)NC2=CC1=C3OCO1 QJQRNDGUWQVAEV-AAFSJPGBSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical group [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 229940039790 sodium oxalate Drugs 0.000 description 1
- HPPWMWCITPGPKK-UHFFFAOYSA-M sodium;1-hydroxy-3-oxododecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCC(=O)CC(O)S([O-])(=O)=O HPPWMWCITPGPKK-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Chemical group 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application relates to the field of pharmacy, in particular to a pharmaceutical application of sodium new houttuyfonate. The sodium new houttuyfonate can be used for preparing medicines for inhibiting Fusobacterium nucleatum.
Description
Technical Field
The application belongs to the field of medicines, and particularly relates to a novel application of sodium new houttuyfonate.
Background
Along with the development of histology, the occurrence and development of various diseases are closely related to infection of Fusobacterium nucleatum. Fusobacterium nucleatum (Fusobacterium nucleatum, fn) is the highest-content Fusobacterium in the oral cavity of humans, often causing various opportunistic infections. Clinical studies show that Fusobacterium nucleatum not only causes oral diseases, but also plays an important role in diseases such as bad pregnancy outcome, tumor and the like. A large amount of Fusobacterium nucleatum is separated from clinical specimens of various diseases such as colon cancer, osteomyelitis, pericarditis, brain abscess and the like. Current studies indicate that the adhesion proteins FadA and Fap2 of fusobacterium nucleatum induce and promote the occurrence and development of inflammatory bowel disease and colon cancer. Mainly shows that (1) the high abundance fusobacterium nucleatum is related to the poor prognosis of patients; (2) the recurrence of cancer may be due in part to the ability of F.nucleatum to promote resistance of colon cancer tissue to chemotherapy.
Colon cancer (Colorectal cancer, CRC) is the second leading cause of cancer-related death worldwide, particularly in individuals under 50 years of age, with a gradual increase in prevalence. CRC is a heterogeneous disease of the intestinal epithelium, characterized by accumulation of mutations and deregulation of the immune response. There is growing evidence that up to 90% of disease risk is due to environmental factors such as diet, consistent with literature reports suggesting CRC-related "oncogenic flora" in recent years. However, unlike the well-known causal role of helicobacter pylori in gastric cancer, no specific microorganism triggering CRC has been identified at present. Thus, it is necessary to decipher the specific pathogen population or metabolite that drives CRC and characterize its underlying mechanism.
Herba Houttuyniae is fresh whole grass or dry aerial part of Houttuynia cordata Thunb. Belonging to Saururaceae, and is originally carried in Ming's medical miscellaneous records. Houttuynin is derived from volatile oil of herba Houttuyniae, and is unstable and easily degradable. At present, sodium bisulfite addition complex sodium new houttuyfonate is often used clinically. The sodium new houttuyfonate (Sodium New Houttuyfonate, SNH) has obvious antibacterial effect and obvious inhibition effect on staphylococcus aureus, escherichia coli, sporotrichosis and the like. Is an antibacterial and anti-inflammatory drug in clinic.
Disclosure of Invention
The application aims to provide a new application of sodium new houttuyfonate.
In particular, the application provides an application of sodium new houttuyfonate in preparing medicines for inhibiting Fusobacterium nucleatum.
In a preferred embodiment, the sodium neohouttuyfonate is used as the sole active ingredient for preparing a medicament for inhibiting Fusobacterium nucleatum.
In another preferred embodiment, the agent that inhibits fusobacterium nucleatum is useful in the treatment of colon cancer.
Details of the various aspects of the application will be described in detail in subsequent sections. The features, objects, and advantages of the application will become more apparent from the description that follows.
Drawings
FIG. 1MIC assay for inhibition of Fn by SNH.
FIGS. 2 (a) to 2 (c) show the effect of SNH on colon cancer and normal cell growth by the CCK-8 method.
Fig. 2 (a), fig. 2 (b), and fig. 2 (c) show the effect of SNH on colon cancer HCT116, colon cancer HT29, and colon epithelial cell growth, respectively.
FIGS. 3a to 3d show the inhibitory effect of SNH on F.nucleatum on the proliferation of colon cancer cells.
FIG. 3a is a graph showing the overall effect of SNH on F.nucleatum on proliferation of colon cancer cells; FIGS. 3b,3c,3d show the inhibition of proliferation of F.nucleatum colon cancer cells by SNH measured over different time periods 24h,48h and 72h, respectively.
Fig. 4 a-4 c SNH significantly inhibited the growth of colon cancer tumors in Fn nude mice.
FIG. 4a is a graph showing colon cancer tumor size in nude mice of control group and SNH administration group and positive control group; FIG. 4b is the colon cancer tumor weight of each group of nude mice; fig. 4c is colon cancer tumor volume for each group of nude mice.
FIG. 5 shows that Fn was enriched in nude mouse colon cancer tumor tissue in this model by RT-PCR.
Detailed Description
Sodium new houttuyfonate (Sodium New Houttuyfonate, SNH), chemical name: sodium bisulfite adduct of dodecanoyl aldehyde, having the formula C14H27NaO5S, relative molecular weight 330.41, has the formula:
sodium New Houttuyfonate (SNH) of the present application is commercially available. The purity of the product meets the medicinal standard. Sodium Neohouttuyfonate (SNH) purity was optimal at > 98%.
Taking Sodium New Houttuyfonate (SNH) of the application as an example. The Sodium New Houttuyfonate (SNH) of the present application may be used alone or in the form of a pharmaceutical composition. The pharmaceutical composition comprises Sodium New Houttuyfonate (SNH) of the present application as a main active ingredient and a pharmaceutically acceptable carrier. In general, the pharmaceutical composition of the present application should contain 0.1 to 99.9% by weight of Sodium Neohouttuyfonate (SNH), an active natural ingredient of the present application. The "pharmaceutically acceptable carrier" does not destroy the pharmaceutical activity of the Sodium New Houttuyfonate (SNH) of the application; meanwhile, the effective dosage can exert the nontoxic and harmful effects on human body when the medicine carrier acts.
The pharmaceutically acceptable carrier includes, but is not limited to: soft phospholipids, aluminum stearate, aluminum oxide, ion exchange materials, self emulsifying drug delivery systems, tween or other surfactants, serum proteins, buffer substances such as phosphates, glycine, sorbic acid, water, salts, electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, magnesium silicate, saturated fatty acid partial glyceride mixtures and the like.
Other commonly used pharmaceutical excipients such as binders (e.g. microcrystalline cellulose), fillers (e.g. starch, glucose, lactose anhydrous and lactose beads), disintegrants (e.g. crospvp, croscarmellose sodium, low substituted hydroxypropylcellulose), absorption enhancers, adsorption carriers, flavours, sweeteners, excipients, diluents, wetting agents, etc.
The Sodium New Houttuyfonate (SNH) and its pharmaceutical compositions of the present application may be prepared by methods conventional in the art and administered by the gastrointestinal route. The oral preparation comprises capsules, tablets, oral liquid, granules, pills and the like. Thus, the route of administration of the Sodium New Houttuyfonate (SNH) and pharmaceutical compositions thereof of the present application should be selected for oral administration.
The application will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present application and are not intended to limit the scope of the present application. The experimental procedures, which do not address the specific conditions in the examples below, are generally carried out under conventional conditions or under conditions recommended by the manufacturer. All percentages, ratios, proportions, or parts are by weight unless otherwise indicated.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present application. The preferred methods and materials described herein are presented for illustrative purposes only.
The above-mentioned features of the application, or of the embodiments, may be combined in any desired manner. All of the features disclosed in this patent specification may be combined with any combination of the features disclosed in this specification, and the various features disclosed in this specification may be substituted for any alternative feature serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, the disclosed features are merely general examples of equivalent or similar features.
Test of antibacterial Activity after action of sodium houttuyfonate on Fn
The experimental method comprises the following steps: and detecting the minimum inhibitory concentration of the traditional Chinese medicine monomer on the fusobacterium nucleatum according to a micro double dilution method. The concentration of the bacterial liquid is adjusted to 10 by the turbidimetry of Maifanitum 8 CFU/mL, test group added with sodium neohouttuyfonate, blank group added with new fishy smell without traditional Chinese medicine monomerThe liquid culture medium of sodium oxalate, solvent group, 0.1% DMSO is added as blank control, each group is provided with 3 repeated holes, and the mixture is fully and uniformly mixed with 1:1 volume of the prepared clostridium nucleatum bacterial liquid, and the mixture is placed in a 37 ℃ incubator for culture. And (3) determining an OD600 value by using a full-wavelength enzyme-labeled instrument so as to determine the MIC value of the traditional Chinese medicine monomer. The test was repeated 3 times.
Experimental results: the minimum bactericidal concentration is the minimum concentration required to kill bacteria. The minimum inhibitory concentration assay was diluted with broth and assayed by passage to drug-free agar plates. After culturing for 18-24h at 37 ℃, observing the growth condition of bacteria, wherein the sterile growth is the minimum sterilization concentration of the tested medicine. As shown in FIG. 1, MIC of sodium new houttuyfonate was determined using a 2-fold serial dilution method. The results show that: the sodium new houttuyfonate has strong antibacterial activity, and the MIC is 200 mu M.
Experiment sodium Di-New houttuyfonate detection of proliferation toxicity of colon cancer cells and colon epithelial cells
The experimental method comprises the following steps: HCT-116, HT29 and 460 cells were observed and when the cell density reached 90%, the cells were digested with 0.25% pancreatin. The digested cells were counted and seeded into 96-well plates with 5000 HCT-116 cells per well. After the cells are attached, adding culture media of sodium neohouttuyfonate with different concentrations into a 96-well plate, and setting 6 repeated groups for each group. Cell viability was measured at 24h,48h, 72h, respectively, medium was removed before measurement, and 10. Mu.L of CCK-8 assay solution was added to each well. Blank wells (with detection solution only) were set, incubated at 37℃for 1-2h, absorbance at 450nm was detected using a microplate reader, and the experiment was repeated 3 times.
Experimental results: as shown in fig. 2 (a) to 2 (c), CCK8 experiments showed that SNH had little effect on cell activity at its effective dose (200 μm) with antibacterial activity after SNH intervention, and most colon cancer cells and colon epithelial cells were able to grow normally.
Experiment detection of inhibition of sodium Trinew houttuyfonate on Fn-infected colon cancer cells
The experimental method comprises the following steps: for cell proliferation assays, a resuspension of HCT-116 cells was performed at 1X 10 cells per well 4 Inoculated in 24-well plates and 2mL of complete medium was added. Incubating cells with fold Fn infectionAnd the cells treated by the metronidazole are used as positive control. Cell counts were performed at 24 hours, 48 hours and 72 hours using a countar cytometer. Each test was repeated 3 times.
Experimental results: as shown in fig. 3a to 3d, the cell count experiment shows that the clostridium nucleatum can significantly promote the proliferation of colon cancer cells, the proliferation level of the cells is significantly reduced after the sodium new houttuyfonate is used for stem prognosis, and the longer the time is, the stronger the inhibition effect of the sodium new houttuyfonate is.
After experimental four new houttuynin sodium acting Fn infected colon cancer model mice, tumor growth condition detection
The experimental method comprises the following steps: nude mice are purchased from Shanghai Laike animal experiment center, and the experiment is started after normal adaptive feeding for 1 week; resuscitates human colon cancer cells HCT-116, subcultures to the third generation, digests the cells with trypsin, centrifugally collects, washes twice with PBS, and suspends to form single cell suspension. Nude mice were inoculated subcutaneously with a microinjector. Macroscopic cancer nodules formed after day 6 inoculation, maximum diameter (a) and minimum diameter (b) of the tumor were measured using vernier calipers, according to the formula v=0.5 x (axb 2 ) Tumor volumes were calculated. Tumors were measured every 3 days. Starting on 9 th day of inoculation, injecting 0.9% NaC1 and Fn at multiple points around the tumor by using a sterile microinjector in a laminar flow ultra-clean workbench every 3 days, wherein the total volume of injection is 100 mu L/tumor; and 0.9% NaCl was injected intraperitoneally with a sterile microinjector to total volume of 100. Mu.L/nude mice. The total injection is 6 times, the electronic analytical balance measures the weight of the tumor on the 2 nd day after the last injection, and the digital single-lens reflex camera is used for photographing. The tumor tissue is preserved in a refrigerator at-80 ℃.
Experimental results: as shown in fig. 4 a-4 c and fig. 5, the clostridium nucleatum can obviously promote the tumor growth of colon cancer mice, when sodium new houttuyfonate acts on Fn infected colon cancer model mice, the tumor cell growth in the mice is obviously inhibited, and after the tumor is taken out, compared with the model group tumor, the tumor growth is obviously reduced, which indicates that the tumor growth is inhibited.
The various aspects of the application have been described above. It will be understood, however, that equivalent changes and modifications may be made thereto by those skilled in the art without departing from the spirit of the application, which changes and modifications likewise fall within the scope of the appended claims.
Claims (2)
1. Application of sodium new houttuyfonate in preparing medicine for inhibiting Fusobacterium nucleatum is provided.
2. Use according to claim 1, characterized in that the sodium new houttuyfonate is used as sole active ingredient for the preparation of a medicament for inhibiting fusobacterium nucleatum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210384916.6A CN114569590B (en) | 2022-04-13 | 2022-04-13 | Medical application of sodium new houttuyfonate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210384916.6A CN114569590B (en) | 2022-04-13 | 2022-04-13 | Medical application of sodium new houttuyfonate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114569590A CN114569590A (en) | 2022-06-03 |
| CN114569590B true CN114569590B (en) | 2023-11-14 |
Family
ID=81779289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210384916.6A Active CN114569590B (en) | 2022-04-13 | 2022-04-13 | Medical application of sodium new houttuyfonate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114569590B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112336744A (en) * | 2020-12-08 | 2021-02-09 | 河南省医药科学研究院 | New houttuynin sodium and its application in preparing antineoplastic medicine by combining with cisplatin |
-
2022
- 2022-04-13 CN CN202210384916.6A patent/CN114569590B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112336744A (en) * | 2020-12-08 | 2021-02-09 | 河南省医药科学研究院 | New houttuynin sodium and its application in preparing antineoplastic medicine by combining with cisplatin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114569590A (en) | 2022-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WAISBREN et al. | A clinical appraisal of neomycin | |
| Woodward et al. | Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever | |
| RU2586289C1 (en) | Therapeutic or prophylactic agents to prevent meibomian gland dysfunction or blocking of meibomian gland | |
| WO2016204169A1 (en) | Therapeutic agent and therapeutic method for peracute or acute mastitis during bovine lactation | |
| CN110772504A (en) | Application of echinocandin as inhibitor | |
| US20230133735A1 (en) | Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome | |
| CN114732818A (en) | Application of anti-idiopathic pulmonary fibrosis medicament nintedanib in tuberculosis treatment | |
| CN114569590B (en) | Medical application of sodium new houttuyfonate | |
| EP0424193B1 (en) | Use of actinonin for the manufacture of a medicament for angiogenesis inhibition | |
| CN115040513B (en) | Application of vitamin B6 and preparation thereof in preparation of medicines for preventing and/or treating infection or inflammation-related diseases | |
| CN111544451A (en) | Composition for resisting helicobacter pylori and application thereof | |
| CN114732814B (en) | Application of urolithin A in preventing and treating allergic rhinitis and allergic asthma | |
| Katz et al. | Nocardia asteroides sinusitis: Presentation as a trimethoprim-sulfamethoxazole responsive fever of unknown origin | |
| Couraud et al. | Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil | |
| Gunnarsson et al. | Liver abscesses due to Staphylococcus aureus in a patient with AIDS who underwent small bowel biopsy: case report and review | |
| Barnes et al. | Neisseria meningitidis: a cause of nosocomial pneumonia | |
| CN110339195A (en) | For treating the quinoline of cholangiocarcinoma | |
| CN117357508B (en) | Application of ciliristat in preparation of medicine for treating primary cholangitis | |
| CN104173354B (en) | Can treating cancer pharmaceutical compositions | |
| US12005050B2 (en) | Methods for preventing or treating H. pylori infection | |
| CN116421602B (en) | New application of flubendazole or derivative thereof | |
| TWI536989B (en) | Use of nifuratel for preparation of medicine for treat infections caused by clostridium species | |
| Felarca et al. | Gentamicin in gonococcal urethritis of Filipino males: dosage and response | |
| JP3490146B2 (en) | Anti-Helicobacter pylori agent | |
| RU2195937C1 (en) | Combined antituberculosis preparation (rizobutol) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |